Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders - Pipelinereview

Summary by Pipelinereview
TOKYO, Japan I December 25, 2024 I Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Chuo-Ku, Tokyo, Japan; “Astellas”) to explore new candidate compounds for targeted protein degraders. Axcelead DDP focuses on targeted protein degradation as the next generation of small-molecule drug discovery and prov…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

JapanJapan
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal